Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Metabolic syndrome (MetS) increases the risk of developing diabetes and cardiovascular disease risk factors that are linked with each other, which is a metabolic dysfunction, which contains a combination of multiple.
It is known that METS plays a role in the development of many diseases such as cardiovascular diseases, stroke, cancer, Alzheimer's. Studies have revealed that neuroinflammation, oxidative stress, abnormal lipid metabolism and impaired vascularization, which play a role in the pathogenesis of MetS, affect the structure of the brain and cognition. Atherosclerosis of the carotid artery, increased brain atrophy and white matter damage are potential explanatory mechanisms that lead to an impact on cognitive skills in patients with MetS. In addition, the existence of MetS components such as obesity, diabetes, hypertension alone also negatively affects cognitive functions, and the level of cognitive influence also increases as the number of components an individual has increases.
The literature reports that learning, executive functions, processing speed, attention/working memory and global cognitive functions are affected in individuals with MetS, but no consensus has been reached on this issue. Some studies say that MetS causes a significant decrease in cognitive functions, while some studies indicate that this difference is not significant.
The aim of our study is to proof the relationship between MetS and cognitive functions with metabolic syndrome components.
H1:There is a relationship between the MetS and cognitive functions.
Voluntary participants who have been diagnosed with MetS and agreed to voluntary health subjects will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into two groups. There will be individuals diagnosed with MetS in the intervention group and healthy individuals who do not have any problems in the control group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MetS Group | it consists of volunteer participants diagnosed with MetS between the ages of 18 and 50. All assessments will be applied to the participants by two different researchers at the same time. |
| |
| Control Group | it will consist of healthy individuals aged 18-50 who do not have any health problems and have volunteered to participate in the study who have undergone a health check within the last 6 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| assessment of cognitive performance | Other | evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of Metabolic Syndrome-waist circumference | Waist Circumference measurement will be recorded with a tape measure in the middle between the last palpable rib and the upper edge of the iliac crest. | once, at baseline |
| Evaluation of Metabolic Syndrome-blood pressure | "Omron" digital blood pressure monitor will be used to measure systolic and diastolic blood pressure. Participants will be asked to rest for 5 minutes before the measurement. | once, at baseline |
| Evaluation of Metabolic Syndrome-triglyceride | Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results. | once, at baseline |
| Evaluation of Metabolic Syndrome-HDL-C | Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results. | once, at baseline |
| Evaluation of Metabolic Syndrome-fasting plasma level | Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results. | once, at baseline |
| Metabolic Syndrome Severity Score | This scoring creates a z-score by considering factors such as age, race, gender, and metabolic syndrome components values. There is a website that automatically calculates the z-score when these data are entered. (https://metscalc.org/metscalc/) |
| Measure | Description | Time Frame |
|---|---|---|
| Mini Mental State Examination | it is a test consisting of 11 questions that evaluate different cognitive parameters, including recording memory, attention and calculation, recall and language, motor function and perception. The maximum score that can be taken from the test is 30 and there is no time limit. In scoring, 24-30 points are normal, 23 points and below indicate mild cognitive impairment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Men and women who have been diagnosed with MetS according to NCEP-ATP III criteria and healthy individuals who do not have any health problems
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Aysenur Erekdag, MSc | Contact | +905548959013 | aysenurerekdag@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ayca Arslanturk, BSc | Bezmialem Vakif University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bezmialem Vakif University | Recruiting | Istanbul | 34093 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35054972 | Background | Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022 Jan 12;23(2):786. doi: 10.3390/ijms23020786. | |
| 11368702 | Background | Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. No abstract available. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| D002908 | Chronic Disease |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| once, at baseline |
| Monreal Cognitive Assessment | This scale consists of parts that evaluate executive functions, attention and concentration, memory, language, abstract thinking, visual-spatial skills, orientation and calculation. The application of MoCA takes about 10 minutes and the total score of the scale is calculated over 30 points. The threshold point value is 21. Scores of 20 or less are considered cognitive dysfunction. | once, at baseline |
| Stroop Test TBAG Form | a neuropsychological test that measures focused attention and the speed of information processing | once, at baseline |
| once, at baseline |
| Visual Reaction Test | the participant sees a red circle appearing on a white screen on the computer at variable time intervals and should press the December key of the computer quickly as soon as he sees the circle. | once, at baseline |
| International Physical Activity Questionnare Short-Form | taking into account the last week, the time spent on walking, moderate and vigorous activities is questioned. | once, at baseline |
| pedometer | A valid and reliable method for comparing the participants' weekly step counts and determining their physical activity levels | once, at baseline |
| 33067992 | Background | Bahchevanov KM, Dzhambov AM, Chompalov KA, Massaldjieva RI, Atanassova PA, Mitkov MD. Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults. Arch Clin Neuropsychol. 2021 May 21;36(4):498-506. doi: 10.1093/arclin/acaa081. |
| 34668083 | Background | Tahmi M, Palta P, Luchsinger JA. Metabolic Syndrome and Cognitive Function. Curr Cardiol Rep. 2021 Oct 19;23(12):180. doi: 10.1007/s11886-021-01615-y. |
| 36281674 | Background | Wichayanrat W, Boripuntakul S, Keawtep P, Worakul P, Sungkarat S. Obesity and Brain Health: The Impact of Metabolic Syndrome and Cardiorespiratory Fitness on Cognitive Performances in Middle-Aged Obese Women. J Prev Alzheimers Dis. 2022;9(4):701-707. doi: 10.14283/jpad.2022.54. |
| D009750 |
| Nutritional and Metabolic Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |